Every Form 4 that Beta Bionics, Inc. (BBNX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BBNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BBNX filings page.
Beta Bionics (BBNX) insider activity: A director reported open-market sales of common stock on 10/31/2025 made under a Rule 10b5-1 plan adopted on July 31, 2025. The filings show two transactions: 1,368 shares sold at a weighted average price of $26.8474 (with individual sale prices ranging from $26.27 to $27.24), and 38 shares sold at $27.70.
Following these sales, the reporting person beneficially owned 9,841 shares, held directly. The form notes that full breakdowns of the number of shares sold at each separate price within the weighted-average transaction are available upon request.
Beta Bionics (BBNX) director reported open-market sales on 10/31/2025 under a Rule 10b5-1 plan adopted July 31, 2025. Two transactions were disclosed: 1,287 shares at a weighted average price of $26.8588 (range $26.27–$27.22) and 119 shares at a weighted average price of $27.4502 (range $27.32–$27.57).
Following these trades, the reporting person directly beneficially owns 9,841 shares. The filing notes full trade breakdowns by price increment are available upon request.